Auto-generated from public data. Not the firm's stated position.
Sound Bioventures appears to focus on early-stage biotech investments in the €1.5M to €3.0M range, with recent portfolio activity suggesting a concentration in specialized therapeutic areas including autoimmune disease, oncology, and rare kidney disease treatments.
Generated 11 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.